Download Files:
Products Details
Product Description
– Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].
Web ID
– HY-132613
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C530H668F10N173Na44O320P43S6
References
– [1]Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282.|[2]Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384(13):1216-1226.
CAS Number
– 1834612-06-4
Molecular Weight
– 17307.71
SMILES
– [Lumasiran (sodium)]
Clinical Information
– Launched
Research Area
– Metabolic Disease
Solubility
– 10 mM in H2O
Target
– Small Interfering RNA (siRNA)
Pathway
– Epigenetics
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
